Since 2020, the impact of the epidemic has led to the suspension of work and production in most parts of the country, more than 90% of residents are facing a sharp decline in income, and long-term losses have led to some people can not afford to pay off their mortgages, some people have lost their jobs
However, everything has disadvantages and benefits, and when most companies are facing bankruptcy crisis, the profits of the pharmaceutical industry have begun to rise rapidly, and even because of the impact of the epidemic, one after another the richest man and giant in the medical industry have been created
On April 12, 2022, a domestic medical device company "Jiuan Medical" announced the pre-revenue report for the first quarter of this year, according to the data, Jiuan Medical in this year's secondary market, three months of net profit has reached nearly 16 billion yuan, according to the average daily revenue, the company's net profit a day is as high as 150 million yuan, rounded to about equal to 1 Zheng Shuang
What is the concept of $16 billion? According to the understanding, the total profit of Jiuan Medical in the past 10 years does not exceed 980 million yuan, and in the few months from the beginning of 2022 to the present, the company's net profit has exceeded 15 times of the total profit in the past 10 years
As a medical company, the reason why it can have such a high revenue, all rely on the "new crown test paper" produced by this company, according to the news, Jiuan Medical's current main product is the new crown antigen household test paper exported to the United States, this test paper can quickly determine the antigen components in the human body within 15 minutes, and improve the accuracy of the new crown test, including the detection of the Omicron variant is also effective
So far, the new crown test paper in the United States is priced at $6.9, and in December last year, Jiuan Medical and the US Ministry of Public Service Medical Company signed a shopping contract of up to 1.7 billion US dollars, equivalent to more than 10 billion yuan, these test strips can be used by 350 million people in the United States for new crown antibody testing, and by March this year, Jiuan Medical has received a total of 7 billion yuan from the other party
A small new crown test strip has doubled the revenue of a domestic company by 15 times, and in addition to Jiuan, other medical companies in our country that have obtained production standards and listing approvals are also selling test papers to different countries, of which Kur Technology, Xiangda Bio, etc. have signed large-scale contracts in the United States, India, the United Kingdom and other regions
It is worth noting that Jiuan Medical was originally known for doing electronic sphygmomanometers, until 2018, Jiuan Medical entered Apple's smart wear list, supporting Apple mobile phones for intelligent pressure measurement, and in the same year, Xiaomi mobile phones also included Jiuan Medical in the ranks of suppliers, this nominal medical device company, in fact, has been in the field of docking intelligent networks
However, due to the slow spread of the new crown in the world, coupled with the popularity of vaccines and the intervention of other medical companies, whether companies such as Jiuan Medical can break the revenue myth in the next year is still a huge challenge
What do you think about this?